38 Participants Needed

JSP191 for Chronic Granulomatous Disease

EM
SA
Overseen BySandra Anaya-O'Brien, R.N.
Age: Any Age
Sex: Any
Trial Phase: Phase < 1
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Do I have to stop taking my current medications for the trial?

The trial protocol does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Do I need to stop my current medications for the trial?

The trial protocol does not specify if you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.

What data supports the idea that JSP191 for Chronic Granulomatous Disease (also known as: JSP191, AMG 191) is an effective treatment?

The available research does not provide specific data on JSP191 for treating Chronic Granulomatous Disease. Instead, it discusses other treatments like hematopoietic stem cell transplantation (HSCT), which has shown improved survival rates of over 84-90%. It also mentions gene therapy as a promising future approach. Without specific data on JSP191, we cannot compare its effectiveness to these treatments.12345

What safety data exists for JSP191 treatment in Chronic Granulomatous Disease?

The provided research does not contain specific safety data for JSP191 or AMG 191 in the treatment of Chronic Granulomatous Disease. The articles focus on the quality of life, immunological aspects, and treatment options like hematopoietic stem cell transplantation and gene therapy for CGD, but do not mention JSP191 or AMG 191.36789

Is the drug JSP191 a promising treatment for Chronic Granulomatous Disease?

The provided research articles do not contain information about JSP191 or its effectiveness for Chronic Granulomatous Disease. Therefore, I cannot determine if JSP191 is a promising treatment based on the given data.1011121314

What is the purpose of this trial?

Background:Chronic granulomatous disease (CGD) is a rare immune disorder that can cause serious infections throughout the body. The only cure for CGD is a stem cell transplant. Transplants from a sibling are best, but many people must get transplants from unrelated donors. However, these transplants can cause serious complications in people with CGD.Objective:To see if a study drug (JSP191) can help improve the success rates of stem cell transplants for people with CGD from an unrelated donor.Eligibility:People aged 4 to 65 years with CGD who require a transplant.Design:Participants will be screened. Part of the screening will help to identify the best match to a transplant donor. Participants will have a physical exam, including dental and eye exams. They will have blood and urine tests. They will have tests of their breathing and heart function. A bone marrow sample will be taken. They will have their stem cells collected.Participants will have a catheter inserted into a vein in their chest. It will remain in place for the entire period of transplant and recovery.Participants will be in the hospital 40 to 50 days for the transplant. This will include a conditioning phase, to prepare their body for the procedure, as well as the transplant and recovery phases. As part of the conditioning phase, participants will receive JSP191 through a vein for 1 hour.After discharge, participants will have follow-up visits 2 times a week for 100 days. Additional follow-up visits will continue for 5 years....

Research Team

EM

Elizabeth M Kang, M.D.

Principal Investigator

National Institute of Allergy and Infectious Diseases (NIAID)

Eligibility Criteria

This trial is for people aged 4-65 with Chronic Granulomatous Disease (CGD) needing a stem cell transplant and have an unrelated matched donor. Participants must be able to stay near the NIH for 3 months post-transplant, use contraception, and not have major illnesses or organ failure that could affect survival after the transplant.

Inclusion Criteria

Has an unrelated matched donor available (but no matched related donor available)
If of childbearing potential, must agree to consistently use contraception from 1 month prior to baseline, throughout study participation, and for 1 year after receiving transplanted cells. Acceptable forms of contraception are: Contraceptive pills or patch, Norplant, Depo-Provera, or other FDA-approved contraceptive method; Male partner has previously undergone a vasectomy
If able to impregnate a partner, must agree to consistently use contraception from the time of enrollment through 3 months post-transplant. Acceptable forms of contraception are: Male condom with spermicide
See 5 more

Exclusion Criteria

I have seizures that are not controlled by medication.
Transaminases > 5x upper limit of normal based on the individual s clinical situation and at the discretion of the investigator
CRP > 100 mg/dL within 6 weeks of the transplant
See 8 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks
Multiple visits for exams and tests

Conditioning

Participants undergo conditioning with JSP191, alemtuzumab, and total body irradiation to prepare for the transplant

1 week
Inpatient hospital stay

Transplant and Recovery

Participants receive a high-dose donor graft infusion followed by post-transplant cyclophosphamide

40-50 days
Inpatient hospital stay

Follow-up

Participants are monitored for safety and effectiveness after treatment, including engraftment and GvHD assessment

104 weeks
2 visits per week for 100 days, then periodic visits up to 5 years

Treatment Details

Interventions

  • JSP191
Trial Overview The study tests JSP191 in patients with CGD undergoing stem cell transplants from unrelated donors. It aims to improve success rates by including a conditioning phase where JSP191 is administered intravenously before the actual transplant procedure.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Single arm studyExperimental Treatment1 Intervention
Eligible CGD patients will receive one time infusion of study product along with Alemtuzumab and TBI as part of HSCT conditioning regimen

Find a Clinic Near You

Who Is Running the Clinical Trial?

National Institute of Allergy and Infectious Diseases (NIAID)

Lead Sponsor

Trials
3,361
Recruited
5,516,000+

Findings from Research

In a study of 85 patients with chronic granulomatous disease (CGD), 8% were identified as having the variant type X91+, with a median age of onset at just 4 months, highlighting the early impact of this condition.
Patients with X91+ CGD showed a wide range of neutrophil function, as indicated by the stimulation index (SI), which suggests that clinical manifestations can vary significantly, and underscores the need for awareness to avoid missed diagnoses.
Variant Type X91+ Chronic Granulomatous Disease: Clinical and Molecular Characterization in a Chinese Cohort.Sun, B., Zhu, Z., Hui, X., et al.[2022]
In a study of 15 patients with p22(phox)-deficient chronic granulomatous disease (CGD), the survival rate after 2 years of age was notably high at 93%, indicating a prolonged survival plateau beyond this age.
Prophylactic treatment with interferon-gamma (IFN-ฮณ) did not significantly reduce the rate of severe infections in these patients, suggesting that its efficacy in preventing infections may be limited.
Long-term outcome of patients with p22 (phox) -deficient chronic granulomatous disease on Jeju Island, Korea.Kang, HS., Hwang, G., Shin, KS.[2020]
Chronic granulomatous disease (CGD) is primarily caused by defects in the NADPH oxidase complex, leading to impaired immune function, but newer forms like NCF4/p40phox deficiency are milder and do not typically result in severe infections.
Hematopoietic stem cell transplantation (HSCT) has shown a significant improvement in survival rates for CGD patients, exceeding 84-90%, and ongoing research into gene therapy and immunomodulators offers promising future treatment options.
Chronic Granulomatous Disease: a Comprehensive Review.Yu, HH., Yang, YH., Chiang, BL.[2021]

References

Variant Type X91+ Chronic Granulomatous Disease: Clinical and Molecular Characterization in a Chinese Cohort. [2022]
Long-term outcome of patients with p22 (phox) -deficient chronic granulomatous disease on Jeju Island, Korea. [2020]
Chronic Granulomatous Disease: a Comprehensive Review. [2021]
Long-term follow-up and outcome of 39 patients with chronic granulomatous disease. [2015]
[A clinical study of haploid hematopoietic stem cells combined with third-party umbilical cord blood transplantation in the treatment of chronic granulomatous disease]. [2020]
Health-Related Quality of Life and Emotional Health in X-Linked Carriers of Chronic Granulomatous Disease in the United Kingdom. [2021]
Immunological Aspects of X-Linked Chronic Granulomatous Disease Female Carriers. [2021]
Case report: HLA-haploidentical HSCT rescued with donor lymphocytes infusions in a patient with X-linked chronic granulomatous disease. [2023]
Exome sequencing reveals RAG1 mutations in a child with autoimmunity and sterile chronic multifocal osteomyelitis evolving into disseminated granulomatous disease. [2021]
Characterization of a major encephalitogenic T cell epitope in SJL/J mice with synthetic oligopeptides of myelin basic protein. [2019]
'Lupus-prone' mice are susceptible to organ-specific autoimmune disease, experimental allergic encephalomyelitis. [2018]
In trans T cell tolerance exacerbates experimental allergic encephalomyelitis by interfering with protective antibody responses. [2021]
E.U. paediatric MOG consortium consensus: Part 1 - Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. [2022]
14.United Statespubmed.ncbi.nlm.nih.gov
Humoral signatures of MOG-antibody-associated disease track with age and disease activity. [2023]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of ServiceยทPrivacy PolicyยทCookiesยทSecurity